MDS Capital

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, founded in 2003. The company specializes in the design and development of non-fusion motion preservation systems for treating degenerative diseases of the cervical and lumbar spine. Its flagship products, the M6-C and M6-L artificial discs, offer innovative options for artificial cervical and lumbar disc replacements, respectively. These discs are uniquely engineered to replicate the anatomical and biomechanical properties of natural intervertebral discs by incorporating an artificial nucleus and annulus. Spinal Kinetics collaborates with spine surgeons to enhance the effectiveness of its devices, which are distributed in various countries, including Australia, Germany, Spain, and the United Kingdom. The company operates as a subsidiary of Orthofix Medical Inc.

Usystems specializes in the design, development, and manufacture of advanced ultrasound systems and software aimed at enhancing breast cancer detection, particularly in women with dense breast tissue. The company's innovative products provide high-quality 3D ultrasound images that assist radiologists in identifying areas of concern within breast tissue. In addition to its focus on medical imaging, Usystems is dedicated to creating cutting-edge racking enclosures and cooling solutions that minimize noise, heat, and operational costs in data centers and office environments. Through a commitment to quality and innovation, Usystems employs state-of-the-art manufacturing processes to deliver effective solutions in both healthcare and data management sectors.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapeutics aimed at addressing significant unmet medical needs. Founded by seasoned pharmaceutical executives, the company is engaged in the commercialization of novel drugs and therapies for challenging illnesses. Ception's portfolio includes Reslizumab, which targets eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents designed for potential oral administration. In addition, the company is actively developing treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. Ception's research efforts are focused on creating new compounds and exploring new indications for existing therapies, underscoring its commitment to advancing healthcare solutions.

Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, founded in 2003. The company specializes in the design and development of non-fusion motion preservation systems for treating degenerative diseases of the cervical and lumbar spine. Its flagship products, the M6-C and M6-L artificial discs, offer innovative options for artificial cervical and lumbar disc replacements, respectively. These discs are uniquely engineered to replicate the anatomical and biomechanical properties of natural intervertebral discs by incorporating an artificial nucleus and annulus. Spinal Kinetics collaborates with spine surgeons to enhance the effectiveness of its devices, which are distributed in various countries, including Australia, Germany, Spain, and the United Kingdom. The company operates as a subsidiary of Orthofix Medical Inc.

Resonant Medical develops, manufactures, and commercializes 3D ultrasound image-guided adaptive radiotherapy products. Its products include Clarity Breast System, an IGRT solution for precise non-ionizing guidance for boost and conformal breast treatments; Clarity Prostate System, an IGRT solution for precise non-invasive guidance for prostate treatments; and Multi-Anatomy System, an IGRT solution for precise non-invasive guidance for soft tissue anatomy IGRT treatments, such as gyne and bladder. Resonant Medical serves physicians, physicists, therapists, and administrators. Fred Francis, Anthony Falco, Luc Sirois, and François Perraton founded it in 2000, with its headquarters in Montreal in Canada, and Elekta acquired it as of May 31, 2010.

Adnavance Technologies is an early-stage developer of direct detection molecular diagnostic tests. The company's patented and ultra-sensitive metalized-DNA (M-DNAâ„¢) technology may eliminate the need for amplification for a large number of these tests. This technology provides many significant advantages over existing methods, including ease of use, time to result and cost. The platform is simple and inexpensive and is expected to receive FDA approval for use by any laboratory.

Guava Technologies, Inc. is a manufacturer of biotechnology and medical devices, specializing in the development and design of products for life science research and clinical diagnostics. The company provides a range of solutions, including flow cytometry systems and assays for cell counting, viability, antibody quantification, apoptosis, and cytotoxicity. These products support various applications in cell biology research and drug discovery, with a particular emphasis on HIV/AIDS monitoring. Founded in 1998 and headquartered in Hayward, California, Guava Technologies operates as a subsidiary of Millipore Corp.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

Inimex Pharmaceuticals Inc. is a biopharmaceutical company based in Burnaby, Canada, specializing in the development and commercialization of innate defense regulators (IDRs). These innovative agents are designed to selectively modulate the body's innate immune responses without inducing inflammation. The company's lead product, IMX942, aims to enhance survival rates, mitigate tissue damage, and decrease the risk of bacterial infections. Inimex's IDRs are intended for the treatment of various infections and conditions related to tissue injury, including ventilator-associated pneumonia, tracheobronchitis, bacteremia, endocarditis, mucositis, and certain cancers. Founded in 2001, Inimex Pharmaceuticals is focused on advancing its clinical-stage products to improve patient outcomes.

ViOptix, Inc. is a medical device company that specializes in tissue oximetry technology, which measures local tissue oxygen saturation. Founded in 1999 and headquartered in Fremont, California, ViOptix develops, manufactures, and markets innovative products designed to improve patient outcomes in various medical settings. Its flagship product, the T.Ox Tissue Oximeter, is a lightweight and portable unit that features a color LCD touchscreen and supports multiple fiber optic sensors. Additionally, the company offers T.Ox Remote Monitoring products that enable wireless data transmission to internet-enabled devices, as well as single-use, pre-sterilized sensors for continuous monitoring. The applications of ViOptix's technology span plastic surgery, critical care, and various medical fields, allowing for real-time assessment of tissue viability, wound healing potential, and the detection of vascular diseases. The company, formerly known as Photonify Technologies, Inc., rebranded to ViOptix, Inc. in 2003.

Pharmasset Inc is a clinical-stage pharmaceutical company focused on the discovery and development of innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Pharmasset's research centers on nucleoside analogs, compounds that inhibit the enzymes necessary for viral replication. Currently, the company's development pipeline includes three key product candidates: Clevudine, which is aimed at treating HBV and is anticipated to enter Phase 3 clinical trials; R7128, a pro-drug designed for the treatment of HCV, currently in Phase 1 trials; and Racivir, an investigational drug for HIV that is undergoing Phase 2 clinical trials. Through these efforts, Pharmasset aims to provide effective treatment options for patients suffering from these viral infections.

Alveolus is a leader in the emerging field of non-vascular interventional stenting through next generation stent technology.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of therapeutic aptamers for the prevention and treatment of both chronic and acute diseases. Established in 2000, Archemix is known for its aptamer product candidates, including ARC1779, which is aimed at treating thrombotic microangiopathies and is also relevant for use in carotid endarterectomy procedures. In addition to its work in these areas, the company is developing aptamer therapeutics targeting various conditions in the fields of cardiovascular health, hematology, and oncology.

TransMolecular, Inc. is a neuroscience biotechnology company dedicated to discovering, developing, and commercializing innovative drugs aimed at diagnosing and treating central nervous system diseases, particularly focusing on cancer and pain management. Founded in July 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that enhance its product discovery and development pipeline. TransMolecular has received significant funding through private placements and Small Business Incentive Research grants from the National Institutes of Health, totaling $1 million for its cancer and pain programs. The company holds over 25 patents and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. Its management team, boasting more than 75 years of combined experience in healthcare, pharmaceutical development, and research, is committed to advancing safe and effective therapeutic solutions for patients with limited treatment options.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Renovis, Inc. is a biopharmaceutical company focused on developing innovative drugs for neurological diseases and disorders. The company is actively engaged in creating treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing advanced techniques in molecular biology, medicinal chemistry, and pharmacology, Renovis identifies and selects small molecule drug candidates that adhere to rigorous development standards. Through a combination of in vitro and in vivo studies, drug metabolism and pharmacokinetics assessments, and toxicological evaluations, Renovis aims to deliver effective therapeutic solutions to address significant unmet medical needs in neurology.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Twinstrand Therapeutics is a biopharmaceutical company focused on discovering and developing biological drugs aimed at treating life-threatening diseases, particularly cancer. The company's lead product, TST10088, is a recombinant protein-based prodrug designed for activation by matrix metalloproteinases that are associated with solid tumors. Founded in 1995 and based in Canada, Twinstrand Therapeutics leverages advanced technologies to enhance drug efficacy and target cancer more effectively. Through its innovative approach, the company aims to address critical medical needs in oncology and improve patient outcomes.

TriVirix International is a U.S.-based manufacturer specializing in the design and production of electro-mechanical medical devices, diagnostic instruments, and life-science equipment. Headquartered in Milaca, Minnesota, the company offers a range of products including ribo printers, point-of-care blood testing analyzers, volumetric infusion pumps, and monitors for vital signs and conscious sedation. TriVirix International focuses on delivering innovative solutions to meet the needs of healthcare providers and enhance patient care.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of therapeutic aptamers for the prevention and treatment of both chronic and acute diseases. Established in 2000, Archemix is known for its aptamer product candidates, including ARC1779, which is aimed at treating thrombotic microangiopathies and is also relevant for use in carotid endarterectomy procedures. In addition to its work in these areas, the company is developing aptamer therapeutics targeting various conditions in the fields of cardiovascular health, hematology, and oncology.

Alveolus is a leader in the emerging field of non-vascular interventional stenting through next generation stent technology.

Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cardio-renal diseases. The company focuses on creating novel small-molecule, receptor-specific therapeutics, including adenosine agonists and antagonists, which are designed to diagnose and treat cardiovascular conditions. Additionally, Aderis is developing leukotriene synthesis inhibitors aimed at managing chronic renal disease. The company also has strategic license agreements that involve late-stage products for treating Parkinson's disease and diagnosing coronary artery disease. By targeting specific proteins to either enhance or inhibit their activity, Aderis aims to improve patient outcomes and quality of life while minimizing side effects associated with treatments.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Salu, Inc. was founded in 1997 to help physician specialists and is currently the premier company creating vertical Internet healthcare "hubs" in the specialty physician market. The Salu Hub, formed on a specialty-by-specialty basis, facilitates daily interaction among physicians, patients and industry partners and provides relevant information, services and products for all Hub participants. The Salu Hub connects these parties and simplifies interaction, communication, information delivery and receipt and the purchase of medical goods and services. Salu allows specialty physicians to leverage the Web to benefit their practices and their relationships with their patients. This approach has resulted in more than 17,000 specialty physician-members registering for Salu services including 50 percent of office-based allergists, 17 percent of cardiologists, 11 percent of pulmonologists and 17 percent of physiatrists in the U.S.

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.